Pharmacoeconomic review report. Ocrelizumab (Ocrevus) (Hoffmann-La roche limited).
Ocrelizumab (Ocrevus) is a recombinant humanized monoclonal antibody that selectively targets and depletes B cells that express CD20, which are thought to contribute to the inflammatory and neurodegenerative pathogenesis of multiple sclerosis (MS). Ocrelizumab is indicated for the treatment of adult...
Saved in:
| Online Access: |
http://www.ncbi.nlm.nih.gov/books/NBK534388/ Full text |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
CADTH,
2017
|
| Series: | Common drug review clinical review report.
|
| Subjects: |
